Financial Performance - The company reported a total revenue of HKD 1.5 billion for the fiscal year 2022, representing a year-over-year increase of 15%[14]. - The company achieved operating revenue of CNY 329.65 million in 2022, representing a year-on-year increase of 5.98%[24]. - The net profit attributable to shareholders was CNY 25.27 million, a decrease of 60.14% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 12.50 million, down 46.36% year-on-year[24]. - The net cash flow from operating activities was CNY 52.74 million, an increase of 21.25% compared to the previous year[24]. - The company reported a significant decrease of 67.48% in profits derived from government subsidies, amounting to CNY 16.13 million[131]. - The company achieved a comprehensive gross margin of 47.67%, an increase of 0.65 percentage points from the previous year[136]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization strategies[14]. Research and Development - Investment in R&D increased by 25% in 2022, focusing on mRNA drug development and high-throughput screening technologies[15]. - The R&D investment accounted for 26.50% of operating revenue, an increase of 2.81 percentage points year-on-year[25]. - The company is currently upgrading its next-generation DEL technology and building a nucleic acid new drug research platform and targeted protein degradation platform, leading to increased R&D expenditures[26]. - The company has established a comprehensive drug optimization system covering various technical aspects, enabling the discovery and development of new molecules up to the clinical trial application stage[78]. - The company has a research team of nearly 80 professionals covering various fields, enhancing its drug development capabilities[73]. - The total R&D investment for the year was approximately ¥87.36 million, representing an 18.58% increase from the previous year, and accounting for 26.50% of the company's revenue[97]. - The company has developed a DNA-encoded compound library (DEL) with over 12 trillion small molecules, making it the largest known physical small molecule compound library globally[105]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[14]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of up to HKD 500 million allocated for this purpose[14]. - The company aims to enhance its core technologies, particularly in DEL technology, to improve compound library diversity and screening success rates[169]. - The company is actively forming a domestic business development team and launching customized services and products, including a one-stop new drug development and transfer service[175]. - The company aims to increase its domestic and international marketing outlets to enhance the depth and breadth of its marketing services, ultimately forming a global marketing service network[175]. Corporate Governance and Management - The company has not proposed any special arrangements for corporate governance in the reporting period[8]. - The company has undergone several management changes, including the appointment of new directors and supervisors in 2022[196]. - The company continues to focus on strengthening its board composition and governance practices through regular elections and appointments[196]. - The company appointed a new CFO, Liu Honghe, on April 27, 2023, replacing the previous financial head, Hu Chunyan, who will continue as the financial director in Chengdu[200]. - The company’s board of directors is actively involved in management changes to enhance operational efficiency[199]. Risks and Challenges - The company has highlighted various risks in its operations, including uncertainties related to government subsidies and the performance of acquired subsidiaries[5]. - The company is cautious about increasing R&D investments in ongoing projects due to rising labor costs and potential market challenges[4]. - The company faces risks related to new drug development failures, particularly as it targets new molecular entities with higher failure rates compared to modified or generic drugs[120]. - The company is exposed to the risk of technological obsolescence in drug discovery methods, as the market evolves rapidly with various screening technologies[120]. - The acquisition of UK company Vernalis may pose management risks due to cultural and operational integration challenges[121]. Product Development and Innovation - The company is developing proprietary nucleic acid drug delivery systems based on its established coding/decoding system and diverse molecular library[74]. - The company has established partnerships with global biopharmaceutical companies and research institutions, enhancing its collaborative research capabilities[34]. - The company aims to become a leading innovative biopharmaceutical enterprise, focusing on small molecule and nucleic acid drug discovery and optimization[38]. - The company has synthesized over 1.2 trillion diverse and drug-like DNA-encoded compounds based on more than 6,000 different scaffold structures, demonstrating its capability in identifying lead compounds for known and emerging biological targets[39]. - The company is advancing four projects in Phase I clinical trials and has two projects ready for IND submission, demonstrating a robust pipeline of new drug candidates[36]. User Engagement and Market Performance - User data showed an increase in active users by 20%, reaching a total of 2 million users by the end of 2022[14]. - The company provided a future outlook, projecting a revenue growth of 10% for 2023, driven by new product launches and market expansion[14]. - The company reported a revenue of $1.5 billion for the fiscal year 2022, representing a 15% increase year-over-year[193]. - User data showed a growth of 25% in active users, reaching 10 million by the end of 2022[193]. - The company completed a strategic acquisition of a biotech firm for $100 million, enhancing its product pipeline[193].

[First Quarter Report 2023](index=1&type=section&id=2023%20First%20Quarter%20Report) [Important Notes](index=1&type=section&id=Important%20Notes) The board guarantees the report's authenticity, and the financial statements are unaudited - The Board of Directors, Supervisory Committee, and senior management guarantee the authenticity, accuracy, and completeness of the quarterly report content[2](index=2&type=chunk) - The first quarter financial statements are **unaudited**[3](index=3&type=chunk) [Key Financial Data](index=1&type=section&id=I.%20Key%20Financial%20Data) This section outlines Q1 2023 financial data, non-recurring items, and explanations for key metric changes [Key Accounting Data and Financial Indicators](index=1&type=section&id=(I)Key%20Accounting%20Data%20and%20Financial%20Indicators) Q1 revenue slightly decreased, net profit was negative, but operating cash flow turned positive amid higher R&D spending Key Accounting Data and Financial Indicators | Item | Current Period Amount (CNY) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 69,572,588.38 | -3.99 | | Net Profit Attributable to Shareholders | -9,393,596.88 | N/A | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | -10,320,244.79 | N/A | | Net Cash Flow from Operating Activities | 19,779,297.51 | N/A | | Basic Earnings Per Share (CNY/Share) | -0.02 | N/A | | Diluted Earnings Per Share (CNY/Share) | -0.02 | N/A | | Total R&D Investment | 20,648,543.13 | 21.28 | | R&D Investment as a Percentage of Operating Revenue (%) | 29.68 | Increased by 6.19 percentage points | Key Balance Sheet Items | Item | End of Current Period (CNY) | End of Prior Year (CNY) | Change from Prior Year-End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 1,656,729,729.98 | 1,668,990,981.13 | -0.73 | | Equity Attributable to Shareholders | 1,290,622,121.35 | 1,302,512,123.62 | -0.91 | [Non-recurring Profit and Loss Items and Amounts](index=2&type=section&id=(II)Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring P&L totaled CNY 926,647.91, primarily driven by government subsidies | Item | Current Period Amount (CNY) | Notes | | :--- | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -3,141.88 | | | Government Grants Included in Current Profit or Loss | 1,097,679.95 | | | Other Non-operating Income and Expenses | 426.87 | | | Less: Income Tax Impact | 168,317.03 | | | Total | 926,647.91 | | [Changes and Reasons for Key Accounting Data and Financial Indicators](index=2&type=section&id=(III)Changes%20and%20Reasons%20for%20Key%20Accounting%20Data%20and%20Financial%20Indicators) Increased R&D spending, positive operating cash flow from collections, and a wider net loss due to lower subsidies are noted - **The ratio of R&D investment to operating revenue increased by 6.19 percentage points**, mainly due to continuous upgrades of the DEL screening technology platform[5](index=5&type=chunk) - **Net cash flow from operating activities was CNY 19.78 million**, a significant turnaround from -CNY 5.80 million in the prior year period, driven by a substantial increase in sales collections[5](index=5&type=chunk) - **Net loss attributable to shareholders was -CNY 9.39 million**, compared to -CNY 7.09 million in the prior year period, primarily due to a decrease in government subsidies received[5](index=5&type=chunk) [Shareholder Information](index=3&type=section&id=II.%20Shareholder%20Information) This section details shareholder count, top ten shareholder holdings, and their relationships as of the report date [Total Number of Common Shareholders and Top Ten Shareholders' Holdings](index=3&type=section&id=(I)Total%20Number%20of%20Common%20Shareholders%20and%20Top%20Ten%20Shareholders'%20Holdings) The company had 11,921 common shareholders, with JIN LI (李进) being the largest shareholder at 20.43% - The total number of common shareholders at the end of the reporting period was **11,921**[7](index=7&type=chunk) Top 10 Shareholders | Shareholder Name | Shareholder Type | Number of Shares Held (Shares) | Shareholding Ratio (%) | Number of Restricted Shares Held (Shares) | | :--- | :--- | :--- | :--- | :--- | | JIN LI(李进) | Foreign Individual | 81,876,948 | 20.43 | 81,876,948 | | Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. | Domestic Non-state-owned Corporation | 54,785,953 | 13.67 | 0 | | Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership) | Other | 38,651,163 | 9.65 | 38,651,163 | | Anji Dongfang Jiayu Enterprise Management Partnership (Limited Partnership) | Other | 33,665,721 | 8.40 | 0 | | Shenzhen Juntian Investment Enterprise (Limited Partnership) | Other | 20,132,314 | 5.02 | 0 | | Zhang Chi | Domestic Individual | 14,540,984 | 3.63 | 0 | | JUMBO KINDNESS LIMITED | Foreign Corporation | 13,815,543 | 3.45 | 0 | | Sichuan Development Securities Investment Fund Management Co., Ltd. - Chuanfa Select No. 3 Private Equity Fund | Other | 13,677,070 | 3.41 | 0 | | Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) | Other | 12,243,377 | 3.06 | 0 | | Juntian Venture Capital Co., Ltd. | Domestic Non-state-owned Corporation | 11,931,448 | 2.98 | 0 | [Top 10 Unrestricted Shareholders' Holdings](index=4&type=section&id=Top%2010%20Unrestricted%20Shareholders'%20Holdings) Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. was the largest unrestricted shareholder | Shareholder Name | Number of Unrestricted Shares Held (Shares) | Share Type and Quantity (Shares) | | :--- | :--- | :--- | | Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd. | 54,785,953 | RMB Ordinary Share 54,785,953 | | Anji Dongfang Jiayu Enterprise Management Partnership (Limited Partnership) | 33,665,721 | RMB Ordinary Share 33,665,721 | | Shenzhen Juntian Investment Enterprise (Limited Partnership) | 20,132,314 | RMB Ordinary Share 20,132,314 | | Zhang Chi | 14,540,984 | RMB Ordinary Share 14,540,984 | | JUMBO KINDNESS LIMITED | 13,815,543 | RMB Ordinary Share 13,815,543 | | Sichuan Development Securities Investment Fund Management Co., Ltd. - Chuanfa Select No. 3 Private Equity Fund | 13,677,070 | RMB Ordinary Share 13,677,070 | | Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) | 12,243,377 | RMB Ordinary Share 12,243,377 | | Juntian Venture Capital Co., Ltd. | 11,931,448 | RMB Ordinary Share 11,931,448 | | Chongqing Boyi Xintian Equity Investment Fund Partnership (Limited Partnership) | 9,507,637 | RMB Ordinary Share 9,507,637 | | Long Star Growth Group Limited | 8,866,101 | RMB Ordinary Share 8,866,101 | [Description of Related Parties or Concerted Actions](index=5&type=section&id=Description%20of%20Related%20Parties%20or%20Concerted%20Actions) The report discloses concerted action relationships among several key shareholders - JIN LI (李进), as the executive partner of Chengdu Juzhi Kechuang Biotechnology Partnership (Limited Partnership), is a party acting in concert with Juzhi Kechuang[9](index=9&type=chunk) - Shenzhen Juntian Investment Enterprise (Limited Partnership) and Juntian Venture Capital Co., Ltd. are parties acting in concert[9](index=9&type=chunk) - Hangzhou Dinghui New Trend Equity Investment Partnership (Limited Partnership) and Long Star Growth Group Limited are parties acting in concert[9](index=9&type=chunk) [Other Matters](index=5&type=section&id=III.%20Other%20Matters) No other significant operational matters requiring investor attention were disclosed for the reporting period - The company did not disclose other significant operational matters requiring investor attention during the reporting period[10](index=10&type=chunk) [Quarterly Financial Statements](index=5&type=section&id=IV.%20Quarterly%20Financial%20Statements) This section presents the unaudited consolidated balance sheet, income statement, and cash flow statement for Q1 2023 [Audit Opinion Type](index=5&type=section&id=(I)Audit%20Opinion%20Type) The quarterly financial statements have not been audited - The quarterly financial statements are **unaudited**[10](index=10&type=chunk) [Consolidated Balance Sheet](index=5&type=section&id=Consolidated%20Balance%20Sheet) Total assets slightly decreased to CNY 1.66 billion, with shifts in current and non-current asset composition | Item | March 31, 2023 (CNY) | December 31, 2022 (CNY) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 270,092,919.60 | 358,002,603.58 | | Trading Financial Assets | 622,425,916.67 | 542,049,777.78 | | Accounts Receivable | 73,097,113.83 | 96,904,322.40 | | Inventories | 29,281,806.09 | 25,269,024.97 | | Total Current Assets | 1,114,551,645.87 | 1,145,184,180.57 | | Intangible Assets | 69,294,219.06 | 51,874,893.82 | | Long-term Deferred Expenses | 49,137,297.51 | 46,328,167.04 | | Total Non-current Assets | 542,178,084.11 | 523,806,800.56 | | Total Assets | 1,656,729,729.98 | 1,668,990,981.13 | | Total Liabilities | 341,278,376.32 | 341,748,374.51 | | Total Equity Attributable to Parent Company | 1,290,622,121.35 | 1,302,512,123.62 | [Consolidated Income Statement](index=8&type=section&id=Consolidated%20Income%20Statement) The company reported a net loss of CNY 9.39 million on revenue of CNY 69.57 million in Q1 2023 | Item | Q1 2023 (CNY) | Q1 2022 (CNY) | | :--- | :--- | :--- | | Total Operating Revenue | 69,572,588.38 | 72,465,855.95 | | Total Operating Costs | 87,582,724.31 | 91,164,576.82 | | R&D Expenses | 20,648,543.13 | 17,024,869.24 | | Operating Profit | -11,549,642.89 | -9,685,546.89 | | Total Profit | -11,552,357.90 | -8,392,138.60 | | Net Profit | -9,294,847.57 | -7,088,441.60 | | Net Profit Attributable to Parent Company Shareholders | -9,393,596.88 | -7,088,441.60 | | Basic Earnings Per Share (CNY/Share) | -0.02 | -0.02 | - **R&D expenses increased by 21.28% YoY** to CNY 20.65 million[15](index=15&type=chunk) - The net after-tax amount of other comprehensive income was **-CNY 3.25 million**, a narrowed loss compared to -CNY 12.91 million in the prior year period[16](index=16&type=chunk) [Consolidated Cash Flow Statement](index=10&type=section&id=Consolidated%20Cash%20Flow%20Statement) Operating cash flow turned positive to CNY 19.78 million, while investing activities resulted in a significant cash outflow | Item | Q1 2023 (CNY) | Q1 2022 (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 19,779,297.51 | -5,800,253.79 | | Net Cash Flow from Investing Activities | -103,309,465.02 | 2,490,146.44 | | Net Cash Flow from Financing Activities | -2,903,899.50 | -15,544,681.65 | | Net Increase in Cash and Cash Equivalents | -89,305,620.50 | -19,955,814.13 | | Cash and Cash Equivalents at End of Period | 267,058,822.40 | 325,529,048.72 | - **Cash received from sales of goods and rendering of services increased by 48.56% YoY** to CNY 98.36 million[18](index=18&type=chunk) - **Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets increased significantly** from CNY 4.77 million to CNY 26.72 million[18](index=18&type=chunk)

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 4 月） | --- | --- | --- | |-------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | 分析师会议 \n 业绩说明会 \n 路演活动 | | | 其他 （电话会议） | | | | 2022 年 4 月 7 日 | 15:30-16:30 （国金医药 创新药前沿技术 | | | 系列专题：成都先导从 | DNA 编码到核酸药物研发专家会） : | | | | 国金医药、淡水泉、长盛基金、贺腾投资、博时基金、华 | | | | 泰自营、永安国富、高毅资产、玖鹏资产 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 5 月） | --- | --- | --- | |-----------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------| | | □特定对象调研 \n□媒体采访 | 分析师会议 \n 业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他 （电话会议） | | | 参与单位名称及 | 2022 年 5 月 20 | 日（业绩说明会） : 通过"上证路演中心"网络平台参与公司 2021 年度业绩说 | | 人员姓名 | 明会的投资者 | | | 时间 | 2022 年 5 月 20 日 | | | 参会方式 | | 上海证券交易所上证路演中心（网址 ...

证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 投资者关系活动记录表 （2022 年 6 月） | --- | --- | --- | |----------------|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | □媒体采访 | 业绩说明会 | | 类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他 （电话会议） | | | | 2022 年 6 月 14 日 | 15:00-16:00 （特定对象调研电话会议） : | | | | 方正证券、易方达基金、凯石基金、中信资管、方正合生、 | | | 汐泰投资、金百镕投资、健顺投资 | | | 参与单位名称及 | 2022 年 ...

成都先导药物开发股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2022 年第三季度报告 证券代码：688222 证券简称：成都先导 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JIN LI（李进）、主管会计工作负责人胡春艳及会计机构负责人（会计主管人 员）邓飞明保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (二)非经常性损益项目和金额 单位：元 币种：人民币 | 项目 | 本报告期金额 | 年初至报告期末 | 说明 | | --- | --- | --- | --- | | | | 金额 | | | 非流动性资产处置损益 | -803.19 | -828.44 | | | 计入当期损益的政府补助，但与公司正常经 | 3,816,122.81 | 10,330,608.75 | | | 营业务密 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[2]. - Revenue for the first half of 2022 reached $500 million, representing a 15% increase compared to the same period last year[14]. - The company's operating revenue for the first half of 2022 was ¥138,716,305.70, a decrease of 10.01% compared to ¥154,137,996.93 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was -¥7,058,056.78, representing a decline of 134.17% from ¥20,657,929.10 in the previous year[22]. - The net cash flow from operating activities was -¥15,345,502.71, down 215.99% from ¥13,229,462.89 in the previous year[22]. - The company reported a comprehensive loss of CNY 18,106,785.17 for the first half of 2022, compared to a comprehensive income of CNY 21,944,031.05 in the previous year[199]. - The company reported a profit margin of 15% for the first half of 2022[200]. User Growth and Market Expansion - User data showed an increase in active users, with the total number of users growing to 1.2 million, up 15% compared to the previous year[2]. - The company has expanded its market presence, entering three new countries in the last quarter[14]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2023[142]. - Revenue from domestic clients reached 28.36 million yuan, a year-on-year increase of 25.42%, accounting for 20.44% of total operating revenue[95]. Product Development and R&D - New product development is underway, with three new drug candidates expected to enter clinical trials by the end of 2022, enhancing the company's pipeline[2]. - New product development includes a pipeline of five clinical candidates expected to enter trials by Q4 2022[14]. - The company has allocated $50 million for research and development in mRNA technology, aiming to enhance therapeutic applications[14]. - The total R&D investment for the current period is ¥42,578,595.46, an increase of 27.02% compared to ¥33,521,471.30 in the same period last year[71]. - The company increased its R&D investment as a percentage of revenue to 30.69%, up by 8.94 percentage points from the previous year[23]. Strategic Acquisitions and Partnerships - A strategic acquisition was completed, acquiring a biotech firm for RMB 200 million, which is expected to enhance the company's R&D capabilities[2]. - The company is pursuing strategic acquisitions to bolster its portfolio, with two potential targets identified[14]. - The company is expanding its market presence, targeting new regions in Asia, with plans to establish partnerships with local distributors[2]. Financial Guidance and Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 30% year-over-year, aiming for a total revenue of RMB 650 million[2]. - Future guidance indicates an expected revenue growth of 20% for the next fiscal year[14]. - The company aims to reach $600 million in total revenue by the end of 2022, reflecting continued growth and expansion efforts[143]. Risk Management and Compliance - The management highlighted the importance of risk management strategies in navigating potential market fluctuations and regulatory changes[2]. - The company is focused on mitigating risks from customer concentration and the potential underperformance in developing new markets[100]. - The company is actively addressing management risks associated with its expanding business scale and the integration of Vernalis[99]. Environmental and Social Responsibility - The company established an ESG committee in the first half of 2022 to develop a comprehensive environmental protection system[130]. - No environmental pollution incidents occurred during the reporting period, and the company did not face any administrative penalties for environmental violations[130]. - The company signed environmental responsibility agreements with all employees to ensure compliance with national environmental laws and regulations[131]. Shareholding and Corporate Governance - The company has a commitment to report any changes in shareholding by its actual controllers and major shareholders[134]. - The company has established a commitment to compensate for any losses incurred due to violations of shareholding commitments[138]. - The company will ensure that all issued shares are free from any false records or misleading statements[146]. - The company guarantees strict adherence to all public commitments made during the issuance and listing process, with corresponding responsibilities for any failures[155].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-over-year growth of 25%[12]. - The company achieved operating revenue of 311.06 million RMB in 2021, representing a year-on-year growth of 27.69%[34]. - The net profit attributable to shareholders for 2021 was approximately ¥63.38 million, a slight decrease of 1.00% from ¥64.02 million in 2020[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥23.30 million, reflecting a significant decline of 45.74% compared to ¥74.23 million in 2020[23]. - The net cash flow from operating activities for 2021 was approximately ¥43.50 million, a substantial increase of 2,643.40% from ¥1.59 million in 2020[23]. - The total assets amounted to approximately ¥1.71 billion, an increase of 3.99% from ¥1.65 billion at the end of 2020[23]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.32 billion, reflecting a 2.97% increase from ¥1.28 billion at the end of 2020[23]. - The company reported a significant increase in cash flow from operating activities, reaching 43.50 million RMB, a year-on-year increase of 2,643.40%[25]. - The company achieved operating revenue of CNY 311.06 million, a year-on-year increase of 27.69%[131]. - The net profit attributable to the parent company was CNY 63.38 million, a decrease of 1.00% year-on-year[130]. - The total revenue for the company reached 81,876,948, with a significant increase of 1,231.07 compared to the previous period[195]. Research and Development - Investment in R&D increased by 15%, totaling RMB 300 million, focusing on mRNA and protein degradation technologies[13]. - The company focused on the research and development of small molecules and nucleic acid drugs, establishing four core technology platforms: DEL technology, FBDD/SBDD, nucleic acid drug development platform, and TPD technology platform[35]. - R&D investment amounted to 73.67 million yuan, accounting for 23.69% of operating revenue, with approximately 20 self-developed drug projects, of which 4 have received clinical trial approval[36]. - The company has a total of 391 R&D personnel, with 96.42% holding a bachelor's degree or higher, including 86 PhDs and 133 master's degrees[37]. - The company has synthesized over one trillion structurally diverse DNA-encoded compounds, demonstrating its capability in screening lead compounds against known and emerging biological targets[38]. - The company is focusing on integrating Vernalis's FBDD/SBDD technology to enhance drug discovery capabilities and expand its overseas research and service platform[34]. - The company has established a comprehensive nucleic acid drug development platform, covering key areas such as bioinformatics, nucleic acid chemistry, and clinical medicine[115]. - The company has developed a reliable encoding/decoding system and a diverse molecular library for nucleic acid drug delivery system development[116]. - The company is actively developing clinical candidates for protein degradation agents, focusing on novel E3 ligands and their expression[83]. - The company has completed the synthesis and screening of a library of chimeric protein degradation compounds, focusing on novel E3 ligase discovery and ligand identification[118]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by 2023[12]. - The company is exploring potential acquisitions to enhance its drug development capabilities, with a budget of RMB 200 million allocated for this purpose[12]. - The company is expanding its marketing service network to ensure steady growth in main business revenue, including establishing a branch in Europe through the acquisition of Vernalis[184]. - The company plans to invest in or acquire innovative companies in related fields to enhance its R&D capabilities and maintain industry leadership[185]. - The company aims to become a global leader in innovative biopharmaceuticals, addressing unmet clinical needs through its diverse drug development services[178]. - The company is committed to improving its human resources management system to attract high-quality research talent, ensuring sustainable development[182]. Corporate Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[187]. - The company has not reported any significant differences in governance compared to regulatory requirements, ensuring compliance with laws and regulations[187]. - The company’s internal control management system has been strengthened in accordance with relevant laws and regulations[187]. - The company has not engaged in any major competitive activities that could adversely affect its operations[187]. - The company’s board committees provide professional advice for major decisions, enhancing the decision-making process[187]. Risks and Challenges - The company faces risks related to new drug development failures, particularly due to the high-risk nature of targeting new molecular entities[123]. - The company is exposed to foreign exchange risks due to a significant portion of revenue being denominated in USD and EUR[127]. - The ongoing COVID-19 pandemic has impacted the company's ability to complete projects on time and has slowed down business development activities[129]. - The company faces competition from both international and domestic firms in the drug discovery sector, particularly in the DEL technology field[128]. - The company has expanded its business scale through the acquisition of Vernalis, which may pose management risks due to cultural and operational differences[125]. Future Outlook - The company provided a future outlook projecting a revenue growth of 20% for 2022, driven by new product launches and market expansion[12]. - The company has set ambitious performance guidance for the next fiscal year, aiming for a revenue growth rate of over 20%[195]. - The company is exploring new strategies to enhance its competitive edge in the market, including partnerships and collaborations[197]. - The company is committed to sustainability initiatives, aiming for a 50% reduction in carbon emissions by 2025[198]. - The company plans to implement new marketing strategies aimed at improving customer engagement and retention rates by 20%[198].

Financial Performance - The company plans to distribute a cash dividend of 0.50 CNY per 10 shares, totaling 20,034,000 CNY, which represents 31.61% of the net profit attributable to shareholders[5]. - The company has not achieved profitability since its listing, indicating ongoing investment in growth and development[4]. - The audit report from Deloitte Huayong confirms the accuracy and completeness of the financial statements[5]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[12]. - The net profit attributable to shareholders for 2021 was approximately ¥63.38 million, a slight decrease of 1.00% from ¥64.02 million in 2020[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥23.30 million, down 45.74% from ¥42.94 million in 2020[23]. - The company's operating revenue for 2021 was approximately ¥311.06 million, representing a 27.69% increase compared to ¥243.60 million in 2020[23]. - The total assets at the end of 2021 were approximately ¥1.71 billion, reflecting a 3.99% increase from ¥1.65 billion at the end of 2020[23]. - The net cash flow from operating activities for 2021 was approximately ¥43.50 million, a significant increase of 2,643.40% compared to ¥1.59 million in 2020[23]. - The company achieved operating revenue of 311.06 million yuan, a year-on-year increase of 27.69%[35]. - The net cash flow from operating activities increased by 2,643.40% to ¥43,496,009.09 compared to the previous period, primarily due to the acquisition of Vernalis in December 2020, which significantly expanded the scope of operations[152]. Research and Development - The company invested RMB 200 million in R&D, focusing on protein degradation technologies and high-throughput screening methods[12]. - The company is focused on expanding its research and development capabilities, particularly in high-throughput sequencing and drug discovery technologies[15]. - The company has synthesized over 1 trillion structurally diverse DNA-encoded compounds, demonstrating its capability in identifying lead compounds for known and emerging biological targets[39]. - The company has developed a robust nucleic acid drug research platform, leveraging its expertise in RNA interference (RNAi) technology and nucleic acid chemistry[76]. - The company has established a comprehensive nucleic acid drug development platform, enhancing its capabilities in RNA interference technology and drug delivery systems[115]. - The company has completed screening for 47 different target types, including challenging targets, showcasing its advanced capabilities in drug discovery[112]. - The company has developed a one-stop drug optimization system covering various technical aspects, including recombinant protein expression and pharmacokinetics[82]. - The company has established partnerships with two leading research institutions to accelerate innovation and product development[200]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 30% increase in market share by 2023[12]. - The company is actively pursuing market expansion in Southeast Asia, targeting a 30% increase in market share within the next two years[194]. - The company plans to enhance its core technologies, including expanding the DEL library and improving the efficiency of small molecule screening, to maintain its industry-leading position[174]. - The company aims to construct a high-standard new drug R&D platform to accelerate the clinical advancement of new drug projects and increase revenue through project transfers[176]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 1 billion RMB earmarked for potential deals[200]. - A strategic acquisition of a biotech firm was completed, enhancing the company's capabilities in mRNA drug development[13]. - A strategic acquisition was announced, with the company acquiring a competitor for $200 million, expected to enhance its product offerings[192]. Risks and Compliance - The company has detailed various operational risks and corresponding mitigation strategies in the report[4]. - The company has a comprehensive risk statement regarding forward-looking statements, highlighting potential discrepancies due to various factors[6]. - The company has no non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company faces risks related to new drug development failures, particularly with projects targeting new biological targets[123]. - The company is exposed to foreign exchange risks due to a high proportion of revenue from overseas, primarily in USD and EUR[127]. Human Resources and Governance - The company employs 391 R&D personnel, with 96.42% holding a bachelor's degree or higher, including 86 PhDs and 133 master's degree holders[37]. - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and effective operations[182]. - The total remuneration for the chairman and general manager, Jin Li, was reported at 335.38 million CNY for the reporting period[188]. - The average age of the key executives is 46 years, suggesting a balance of experience and innovation[190]. - The company has seen a delay in the appointment of several key positions, which may impact future operations[190]. Future Outlook - The company provided a forward-looking guidance of 20% revenue growth for the next fiscal year, projecting revenues to reach RMB 1.44 billion[12]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[200]. - The company plans to implement new marketing strategies aimed at increasing customer engagement by 40%[192]. - The company is committed to sustainability initiatives, aiming to reduce carbon emissions by 20% over the next three years[193].

成都先导药物开发股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2022 年第一季度报告 证券代码：688222 证券简称：成都先导 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 JIN LI（李进）、主管会计工作负责人胡春艳及会计机构负责人（会计主管人员）邓 飞明保证季度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | | 本报告期比上年 | | --- | --- | --- | --- | | | | | 同期增减变动幅 | | | | | 度(%) | | 营业收入 | | 72,465,855.95 | 4.77 | | 归属于上市公司股东的净利润 | | -7,088,441.60 | -222.60 | | 归属 ...